Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.05+0.01 (+0.25%)
Close on Nov 17, 2026Market cap $336.94MP/E –Yield –
Opus Genetics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Opus Genetics's operating income for the twelve months ending Jun 30, 2026 was -$50.61M. For fiscal 2025 it was -$38.60M. The highest annual figure on record is $18.23M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.60M | – |
| FY2024 | Dec 31, 2024 | -$62.07M | – |
| FY2023 | Dec 31, 2023 | -$10.56M | -158.0% |
| FY2022 | Dec 31, 2022 | $18.23M | – |
| FY2021 | Dec 31, 2021 | -$22.71M | – |
| FY2020 | Dec 31, 2020 | -$19.97M | – |
| FY2019 | Dec 31, 2019 | -$4.19M | – |
| FY2018 | Dec 31, 2018 | -$20.54M | – |
| FY2017 | Dec 31, 2017 | -$17.35M | – |
| FY2016 | Dec 31, 2016 | -$16.41M | – |
| FY2015 | Dec 31, 2015 | -$18.26M | – |
| FY2014 | Dec 31, 2014 | -$13.27M | – |
| FY2013 | Dec 31, 2013 | -$7.98M | – |
| FY2012 | Dec 31, 2012 | -$6.58M | – |
| FY2011 | Dec 31, 2011 | -$16.13M | – |
| FY2010 | Dec 31, 2010 | -$10.31M | – |
| FY2009 | Dec 31, 2009 | -$6.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.01M | -225.4% |
| Q2 FY2024 | Jun 30, 2024 | -$8.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.43M | -115.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.39M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.13M | – |
| Q4 FY2022 | Dec 31, 2022 | $34.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.51M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.15M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.19M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.02M | -379.7% |
| Q3 FY2020 | Sep 30, 2020 | -$1.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.74M | – |
| Q4 FY2019 | Dec 31, 2019 | $5.01M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.99M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.94M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.68M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.89M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.90M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.22M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.28M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.92M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.72M | – |
See a number that looks wrong?